Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
- Doehn, J. M.
- Tabeling, C.
- Biesen, R.
- Saccomanno, J.
- Madlung, E.
- Pappe, E.
- Gabriel, F.
- Kurth, F.
- Meisel, C.
- Corman, V. M.
- Hanitsch, L. G.
- Treskatsch, S.
- Heim, K.
- Stegemann, M. S.
- Ruwwe-Glösenkamp, C.
- Müller-Redetzky, H. C.
- Uhrig, A.
- Somasundaram, R.
- Spies, C.
- von Bernuth, H.
- Hofmann, J.
- Drosten, C.
- Suttorp, N.
- Witzenrath, M.
- Sander, L. E.
- Hübner, R. H.
Keywords
- Cd169
- Covid-19
- SARS-CoV-2
- Siglec1
- Type I interferons
- recently regarding the diagnostic of SARS-CoV-2 by antibody testing. Dr. Christoph
- Tabeling is participant in the BIH-Charité Clinician Scientist Program funded by the
- Charité-Universitätsmedizin Berlin and the Berlin Institute of Health. The other
- authors declare no conflicts of interest.
